Keros Therapeutics

Merck & Co. is stopping its second Phase III trial of its pulmonary arterial hypertension drug Winrevair (sotatercept) in as many months due to confidence in the drug, this time in an earlier sett

Keros Therapeutics’ ambitions to go up against Merck & Co’s Winrevair with its investigational pulmonary arterial hypertension therapy, cibotercept, have taken a knock after safety concerns halted

Keros Therapeutics has secured Takeda as a partner for one of its two mid-stage drug candidates, allowing the company to extend its cash runway and focus R&D investment on the other. The companies

The state of the financial markets for biopharmaceutical companies in 2024 is about as unpredictable as the weather in San Francisco during the annual J.P. Morgan Healthcare Conference. The forecast f